Summary We studied the clinical significance of the soluble cytokeratin 19 fragment detected with monoclonal antibody CYFRA 21-1 in the sera of patients with histologically proven gastric cancer. Sera of 110 patients with gastric cancer were analysed for CYFRA 21-1 levels by a two-step sandwich enzyme immunoassay. There were no significant differences between CYFRA 21-1 levels and the histotype, depth of invasion or vessel invasion. However, CYFRA 21-1 was significantly higher in the presence of peritoneal metastases, liver metastases and extensive nodal involvement. When the positive cut-off value was defined as 5 ng ml-l, the CYFRA 21-1 in the stage IV and recurrent cases was 55.6% and 66.7%, respectively, which was as high as carcinoembryonic antigen (CEA) and greater than carbohydrate antigen 19-9 (CA 19-9). The positivities in stage I/II and HI were zero and 5.9%, respectively, and false-positive rate in 76 patients with benign gastrointestinal disorders was 2.6%. There appeared to be no correlation between CYFRA 21-1 and CEA or CA 19-9. The patients with above 5 n ml-of CYFRA 21-1 had a significantly poorer prognosis. Multivariate analysis indicated that CYFRA 21-1 was an independent prognostic factor, while CEA and CA 19-9 failed to be of prognostic value. In conclusion, CYFRA 21-1 is a reliable tumour marker for gastric cancer in predicting very advanced cases, recurrence of the disease and overall poor prognosis.
Many clinically useful epitopes of tumour-associated antigens belong to glycoproteins shedding from the cell surface, i.e. CEA, CA 19-9, sialyl Tn antigen and alpha-fetoprotein (AFP). CYFRA 21-1 is unique in that its epitope is from a polypeptide which is most likely released following cell death (Stieber et al., 1993a) . CYFRA 21-1, which recognises soluble cytokeratin 19 fragments (BodenmUiller et al., 1992 (BodenmUiller et al., , 1994a , has been introduced as the most sensitive tumour marker for lung carcinomas, except for small-cell lung cancer (Pujol et al., 1993; Stieber et al., 1993a,b; van der Gaast et al., 1994; Takada et al., 1995) . Aside from lung cancer, CYFRA 21-1 has been reported in uterine carcinomas (Ferdeghini et al., 1993; Bonfrer et al., 1994) and head and neck carcinomas (Doweck et al., 1995) . Little is known, however, about the clinical significance of serum CYFRA 21-1 titres in gastric cancer. In this study, the association between serum CYFRA 21-1 level and the clinicopathological features and prognosis in patients with gastric cancer was studied. Further, the clinical usefulness of CYFRA 21-1 as a tumour marker in gastric cancer was considered.
Materials and metos Patients
The sera from 110 patients with gastric cancer was obtained between January and December 1992 at the First Department of Surgery, Osaka City University Medical School, and was measured for CYFRA 21-1. The patients consisted of 101 primary and 9 recurrent cases. All living patients were followed for more than 30 months. Additionally, we measured CYFRA 21-1 levels in the sera of 100 healthy individuals and in 76 patients with benign disorders of the gastrointestinal tract. The serum samples were stored at -70°C until assayed. Clinicopathological features and staging were classified according to the Japanese Classification of Gastric Carcinoma (1995) . The survival period was defined as the time after the serum sample was taken until the day of death.
Assay
The measurement of CYFRA 21-1 was completed in a twostep sandwich enzyme immunoassay using the Enzymun-test kit for CYFRA 21-1 (Boehringer Mannheim, Mannheim, Germany) as previously described (Takada et al., 1995 In the patients with primary gastric cancer, the serum CYFRA 21-1 titre ranged from 0.4 to 110 ngml -' with a median value of 1.6 ng ml-'. The median value was significantly higher than that of healthy controls, although it was not significantly higher than that of patients with benign gastrointestinal disorders (Table I) .
There was no significant difference among the serum The main sites of metastases for gastric cancer were the intraperitoneal cavity, liver and lymph nodes. Figure 1 shows serum CYFRA 21-1 titres according to the metastatic status. For peritoneal metastases, the serum CYFRA level was significantly elevated from PO to P2 (Kruskal-Wallis test). The median value of serum CYFRA 21-1 for patients with peritoneal metastases (P1, P2) was significantly higher than those without peritoneal metastasis (PO) by the MannWhitney U-test (2.6 ng ml-l vs 1.5 ng ml-'). The serum CYFRA 21-1 titre differed by the status of the liver metastases (Kruskal-Wallis test). Mann-Whitney U-test showed significant differences between the CYFRA 21-1 median values of patients with and without liver metastases (8.1 ng ml-' vs 1.5 ng ml-'). As for lymph node involvement, CYFRA 21-1 levels differed significantly according to the metastatic status (Kruskal-Waflis test). Patients with marked lymph node metastases (n3, n4) had significantly higher serum CYFRA 21-1 levels than patients from nO to n2 (Mann-Whitney U-test; median value, 2.5 ng ml-' vs 1.5 ng ml-'). Figure 2 shows (Steinert and Roop, 1988) .
We defined the cut-off value as 5.0 ng ml-' to select for 
It n 1532 advanced cases of gastric cancer from the distribution of serum CYFRA 21-1 titres in our series (Figure 3 ). This value is a little higher than the cut-off level of 3.5 ng ml1-recommended by the Japan CYFRA research group to distinguish between benign and malignant lung disease (Sugama et al., 1994) . When the cut-off value of 5.0 ng ml-' was employed, the sensitivities of serum CYFRA 21-1 in patients with stage IV and recurrent gastric cancer were quite high, although overall sensitivity for primary gastric cancer was 6.0%. This phenomenon might be related to the release mechanism of cytokeratins. These levels should appear elevated in serum after the tumour grows to an appropriate size with subsequent necrosis. The false-positive rate in benign gastrointestinal disorders was 2.6% (2 of 76 cases). In benign disease of the gastrointestinal tract, the patients with the liver cirrhosis showed relatively high serum CYFRA 21-1 levels coinciding with other reports (Molina et al., 1994) . Accordingly, this must be taken into account when evaluating patients with gastric cancer complicated with liver cirrhosis.
Moreover, the patient whose serum CYFRA 21-1 level was above 5 ng ml-' overall had a significantly poorer prognosis. Multivariate analysis also showed that serum CYFRA 21-1 could function as an independent prognostic determinant, although the hazard ratio was 1.052 indicating it did not add strong prognostic information.
There was no correlation between CYFRA 21-1 and CEA or CA 19-9 levels, indicating the potential usefulness in combining these markers to detect advanced or recurrent gastric cancer. Similar results were reported in lung cancer studies (Sugama et al., 1994; van der Gaast et al., 1994) . Indeed, the combination of these markers improved the sensitivity.
Finally, the measurement of serum CYFRA 21-1 in patients with gastric cancer has proven to be clinically useful for selecting patients with very advanced disease, monitoring for tumour recurrence and predicting the overall prognosis.
